{"transactions":[{"id":740361,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T16:05:29.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":25800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":25800,"derivative":{"exercise_price":17.1,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":25800},"source":{"system":"sec-edgar","filing":"0001193125-26-269365","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000119312526269365/ownership.xml","form_type":"4"}},{"id":746630,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T16:15:16.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":false,"shares":11580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units vested on June 5, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units vested on June 5, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11580},"source":{"system":"sec-edgar","filing":"0001172252-26-000002","document":"form4-06082026_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000117225226000002/form4-06082026_040612.xml","form_type":"4"}},{"id":746629,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T16:15:16.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":10987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":10987,"derivative":{"underlying":"Common Stock","underlying_shares":10987},"source":{"system":"sec-edgar","filing":"0001172252-26-000002","document":"form4-06082026_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000117225226000002/form4-06082026_040612.xml","form_type":"4"}},{"id":746628,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T16:15:16.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":42350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":42350,"derivative":{"exercise_price":4.71,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":42350},"source":{"system":"sec-edgar","filing":"0001172252-26-000002","document":"form4-06082026_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000117225226000002/form4-06082026_040612.xml","form_type":"4"}},{"id":746627,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T16:15:16.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":true,"shares":11580,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":25540,"source":{"system":"sec-edgar","filing":"0001172252-26-000002","document":"form4-06082026_040612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000117225226000002/form4-06082026_040612.xml","form_type":"4"}},{"id":1110152,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T16:05:03.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":30700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":30700,"derivative":{"exercise_price":4.91,"expiration_date":"2035-06-13","underlying":"Common Stock","underlying_shares":30700},"source":{"system":"sec-edgar","filing":"0000950170-25-086699","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000095017025086699/ownership.xml","form_type":"4"}},{"id":1118373,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-09T16:20:31.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":false,"shares":4793,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units vested on June 6, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units vested on June 6, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4793},"source":{"system":"sec-edgar","filing":"0001415889-25-016252","document":"form4-06092025_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000141588925016252/form4-06092025_040612.xml","form_type":"4"}},{"id":1118372,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-09T16:20:31.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":11580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":11580,"derivative":{"underlying":"Common Stock","underlying_shares":11580},"source":{"system":"sec-edgar","filing":"0001415889-25-016252","document":"form4-06092025_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000141588925016252/form4-06092025_040612.xml","form_type":"4"}},{"id":1118371,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T16:20:31.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":42350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 5, 2025, subject to the Reporting Person's Continuous Service (as defined in the Plan) through each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":42350,"derivative":{"exercise_price":1.56,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":42350},"source":{"system":"sec-edgar","filing":"0001415889-25-016252","document":"form4-06092025_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000141588925016252/form4-06092025_040612.xml","form_type":"4"}},{"id":1118370,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T16:20:31.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":true,"shares":4793,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":13960,"source":{"system":"sec-edgar","filing":"0001415889-25-016252","document":"form4-06092025_040612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000141588925016252/form4-06092025_040612.xml","form_type":"4"}},{"id":1481019,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-13T16:30:13.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":22100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":22100,"derivative":{"exercise_price":4.16,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":22100},"source":{"system":"sec-edgar","filing":"0000950170-24-073064","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000095017024073064/ownership.xml","form_type":"4"}},{"id":1485313,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-10T16:15:14.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":4793,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy."}],"balance_after":4793,"derivative":{"underlying":"Common Stock","underlying_shares":4793},"source":{"system":"sec-edgar","filing":"0001415889-24-016193","document":"form4-06102024_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000141588924016193/form4-06102024_040605.xml","form_type":"4"}},{"id":1485312,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-10T16:15:14.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":15750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest in twelve equal monthly installments commencing July 6, 2024, subject to Reporting Person's continuous service through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy."}],"balance_after":15750,"derivative":{"exercise_price":1.03,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":15750},"source":{"system":"sec-edgar","filing":"0001415889-24-016193","document":"form4-06102024_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000141588924016193/form4-06102024_040605.xml","form_type":"4"}},{"id":1493021,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-04T16:30:09.000Z","date":"2024-06-01","kind":"exercise","planned":false,"acquired":false,"shares":4660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vested on June 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vested on June 1, 2024."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4660},"source":{"system":"sec-edgar","filing":"0001415889-24-015360","document":"form4-06042024_040604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000141588924015360/form4-06042024_040604.xml","form_type":"4"}},{"id":1493020,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T16:30:09.000Z","date":"2024-06-01","kind":"exercise","planned":false,"acquired":true,"shares":4660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":9167,"source":{"system":"sec-edgar","filing":"0001415889-24-015360","document":"form4-06042024_040604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000141588924015360/form4-06042024_040604.xml","form_type":"4"}},{"id":1848071,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-21T16:09:11.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":31238,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued."}],"balance_after":31238,"derivative":{"exercise_price":1.47,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":31238},"source":{"system":"sec-edgar","filing":"0001415889-23-010090","document":"form4-06212023_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000141588923010090/form4-06212023_080601.xml","form_type":"4"}},{"id":1854719,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-15T16:28:31.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 14, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":20500,"derivative":{"exercise_price":6.59,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001209191-23-037352","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919123037352/doc4.xml","form_type":"4"}},{"id":1867589,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-05T16:53:44.000Z","date":"2023-06-02","kind":"exercise","planned":false,"acquired":false,"shares":4507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units vested on June 2, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units vested on June 2, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4507},"source":{"system":"sec-edgar","filing":"0001209191-23-034411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919123034411/doc4.xml","form_type":"4"}},{"id":1867588,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-05T16:53:44.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":4660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date."}],"balance_after":4660,"derivative":{"underlying":"Common Stock","underlying_shares":4660},"source":{"system":"sec-edgar","filing":"0001209191-23-034411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919123034411/doc4.xml","form_type":"4"}},{"id":1867587,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-05T16:53:44.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":15750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date."}],"balance_after":15750,"derivative":{"exercise_price":8.7,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":15750},"source":{"system":"sec-edgar","filing":"0001209191-23-034411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919123034411/doc4.xml","form_type":"4"}},{"id":1867586,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T16:53:44.000Z","date":"2023-06-02","kind":"exercise","planned":false,"acquired":true,"shares":4507,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":4507,"source":{"system":"sec-edgar","filing":"0001209191-23-034411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919123034411/doc4.xml","form_type":"4"}},{"id":2118346,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-14T16:51:41.000Z","date":"2022-11-14","kind":"sale","acquired":false,"shares":1371,"price":17.08,"value":23416.68,"ownership":{"direct":false,"nature":"By Aisling Capital IV LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are owned directly by Aisling Capital IV, LP (\"Aisling\"), and held indirectly by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the \"Managers\") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":434455,"source":{"system":"sec-edgar","filing":"0001209191-22-056644","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122056644/doc4.xml","form_type":"4"}},{"id":2118345,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-14T16:51:41.000Z","date":"2022-11-11","kind":"sale","acquired":false,"shares":41160,"price":17.0597,"value":702177.252,"ownership":{"direct":false,"nature":"By Aisling Capital IV LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are owned directly by Aisling Capital IV, LP (\"Aisling\"), and held indirectly by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the \"Managers\") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":435826,"source":{"system":"sec-edgar","filing":"0001209191-22-056644","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122056644/doc4.xml","form_type":"4"}},{"id":2118344,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-14T16:51:41.000Z","date":"2022-11-10","kind":"sale","acquired":false,"shares":11395,"price":17.0246,"value":193995.317,"ownership":{"direct":false,"nature":"By Aisling Capital IV LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.165, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are owned directly by Aisling Capital IV, LP (\"Aisling\"), and held indirectly by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the \"Managers\") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":476986,"source":{"system":"sec-edgar","filing":"0001209191-22-056644","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122056644/doc4.xml","form_type":"4"}},{"id":2131761,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-26T19:09:14.000Z","date":"2022-10-26","kind":"sale","acquired":false,"shares":14540,"price":17.005,"value":247252.7,"ownership":{"direct":false,"nature":"By Aisling Capital IV LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are owned directly by Aisling Capital IV, LP (\"Aisling\"), and held indirectly by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the \"Managers\") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":488381,"source":{"system":"sec-edgar","filing":"0001209191-22-054675","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122054675/doc4.xml","form_type":"4"}},{"id":2131760,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-26T19:09:14.000Z","date":"2022-10-25","kind":"sale","acquired":false,"shares":12018,"price":17.0175,"value":204516.315,"ownership":{"direct":false,"nature":"By Aisling Capital IV LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are owned directly by Aisling Capital IV, LP (\"Aisling\"), and held indirectly by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the \"Managers\") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":502921,"source":{"system":"sec-edgar","filing":"0001209191-22-054675","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122054675/doc4.xml","form_type":"4"}},{"id":2131759,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-26T19:09:14.000Z","date":"2022-10-24","kind":"sale","acquired":false,"shares":14616,"price":17.0078,"value":248586.0048,"ownership":{"direct":false,"nature":"By Aisling Capital IV LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.085, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are owned directly by Aisling Capital IV, LP (\"Aisling\"), and held indirectly by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the \"Managers\") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":514939,"source":{"system":"sec-edgar","filing":"0001209191-22-054675","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122054675/doc4.xml","form_type":"4"}},{"id":2134900,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-19T16:49:33.000Z","date":"2022-10-18","kind":"sale","acquired":false,"shares":32093,"price":16.8891,"value":542021.8863,"ownership":{"direct":false,"nature":"By Aisling Capital IV LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.23 to $17.1023, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are owned directly by Aisling Capital IV, LP (\"Aisling\"), and held indirectly by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the \"Managers\") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":529555,"source":{"system":"sec-edgar","filing":"0001209191-22-054075","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122054075/doc4.xml","form_type":"4"}},{"id":2134899,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-19T16:49:33.000Z","date":"2022-10-17","kind":"sale","acquired":false,"shares":19944,"price":16.0493,"value":320087.2392,"ownership":{"direct":false,"nature":"By Aisling Capital IV LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are owned directly by Aisling Capital IV, LP (\"Aisling\"), and held indirectly by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the \"Managers\") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":561648,"source":{"system":"sec-edgar","filing":"0001209191-22-054075","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122054075/doc4.xml","form_type":"4"}},{"id":2139416,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-11T16:35:38.000Z","date":"2022-10-07","kind":"sale","acquired":false,"shares":7324,"price":16.1591,"value":118349.2484,"ownership":{"direct":false,"nature":"By Aisling Capital IV LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are owned directly by Aisling Capital IV, LP (\"Aisling\"), and held indirectly by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the \"Managers\") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":581592,"source":{"system":"sec-edgar","filing":"0001209191-22-053312","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122053312/doc4.xml","form_type":"4"}},{"id":2141488,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-06T17:58:39.000Z","date":"2022-10-06","kind":"sale","acquired":false,"shares":37839,"price":16.537,"value":625743.543,"ownership":{"direct":false,"nature":"By Aisling Capital IV LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are owned directly by Aisling Capital IV, LP (\"Aisling\"), and held indirectly by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the \"Managers\") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":588916,"source":{"system":"sec-edgar","filing":"0001209191-22-053003","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122053003/doc4.xml","form_type":"4"}},{"id":2141487,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-06T17:58:39.000Z","date":"2022-10-04","kind":"sale","acquired":false,"shares":7700,"price":16.0076,"value":123258.52,"ownership":{"direct":false,"nature":"By Aisling Capital IV LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are owned directly by Aisling Capital IV, LP (\"Aisling\"), and held indirectly by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the \"Managers\") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":626755,"source":{"system":"sec-edgar","filing":"0001209191-22-053003","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122053003/doc4.xml","form_type":"4"}},{"id":2224424,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T18:43:39.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":15619,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the total shares on the one year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued."}],"balance_after":15619,"derivative":{"exercise_price":1.31,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":15619},"source":{"system":"sec-edgar","filing":"0001209191-22-038760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122038760/doc4.xml","form_type":"4"}},{"id":2225826,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-21T16:57:02.000Z","date":"2022-06-17","kind":"sale","acquired":false,"shares":19565,"price":15.1428,"value":296268.882,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-038451","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122038451/doc4.xml","form_type":"4"}},{"id":2230318,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T16:31:30.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2023 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":15000,"derivative":{"exercise_price":7.66,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-22-037429","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122037429/doc4.xml","form_type":"4"}},{"id":2242682,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-06T17:36:48.000Z","date":"2022-06-03","kind":"exercise","acquired":false,"shares":3356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units vested on June 3, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units vested on June 3, 2022."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3356},"source":{"system":"sec-edgar","filing":"0001209191-22-034617","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122034617/doc4.xml","form_type":"4"}},{"id":2242681,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-06T17:36:48.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":4507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date."}],"balance_after":4507,"derivative":{"underlying":"Common Stock","underlying_shares":4507},"source":{"system":"sec-edgar","filing":"0001209191-22-034617","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122034617/doc4.xml","form_type":"4"}},{"id":2242680,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-06T17:36:48.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":15750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date."}],"balance_after":15750,"derivative":{"exercise_price":14.48,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":15750},"source":{"system":"sec-edgar","filing":"0001209191-22-034617","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122034617/doc4.xml","form_type":"4"}},{"id":2242679,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T17:36:48.000Z","date":"2022-06-03","kind":"exercise","acquired":true,"shares":3356,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":19565,"source":{"system":"sec-edgar","filing":"0001209191-22-034617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122034617/doc4.xml","form_type":"4"}},{"id":2648146,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}}],"security":"Series B Preferred Stock","published_at":"2021-07-01T18:29:04.000Z","date":"2021-06-29","kind":"exercise","acquired":false,"shares":1936834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Aisling Capital IV, LP (\"Aisling\").  Aisling Capital Partners IV, LP (\"Aisling GP\"), is the general partner of Aisling, and Aisling Capital Partners IV LLC (\"Aisling Partners\"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":458360},"source":{"system":"sec-edgar","filing":"0001209191-21-044561","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919121044561/doc4.xml","form_type":"4"}},{"id":2648145,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}}],"security":"Series A Preferred Stock","published_at":"2021-07-01T18:29:04.000Z","date":"2021-06-29","kind":"exercise","acquired":false,"shares":8000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Aisling Capital IV, LP (\"Aisling\").  Aisling Capital Partners IV, LP (\"Aisling GP\"), is the general partner of Aisling, and Aisling Capital Partners IV LLC (\"Aisling Partners\"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1893232},"source":{"system":"sec-edgar","filing":"0001209191-21-044561","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919121044561/doc4.xml","form_type":"4"}},{"id":2648144,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}}],"security":"Common Stock","published_at":"2021-07-01T18:29:04.000Z","date":"2021-06-29","kind":"purchase","acquired":true,"shares":187500,"price":16,"value":3000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Aisling Capital IV, LP (\"Aisling\").  Aisling Capital Partners IV, LP (\"Aisling GP\"), is the general partner of Aisling, and Aisling Capital Partners IV LLC (\"Aisling Partners\"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":2834910,"source":{"system":"sec-edgar","filing":"0001209191-21-044561","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919121044561/doc4.xml","form_type":"4"}},{"id":2648143,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}}],"security":"Common Stock","published_at":"2021-07-01T18:29:04.000Z","date":"2021-06-29","kind":"exercise","acquired":true,"shares":458360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Aisling Capital IV, LP (\"Aisling\").  Aisling Capital Partners IV, LP (\"Aisling GP\"), is the general partner of Aisling, and Aisling Capital Partners IV LLC (\"Aisling Partners\"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":2647410,"source":{"system":"sec-edgar","filing":"0001209191-21-044561","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919121044561/doc4.xml","form_type":"4"}},{"id":2648142,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}}],"security":"Common Stock","published_at":"2021-07-01T18:29:04.000Z","date":"2021-06-29","kind":"exercise","acquired":true,"shares":1893232,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Aisling Capital IV, LP (\"Aisling\").  Aisling Capital Partners IV, LP (\"Aisling GP\"), is the general partner of Aisling, and Aisling Capital Partners IV LLC (\"Aisling Partners\"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":2189050,"source":{"system":"sec-edgar","filing":"0001209191-21-044561","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919121044561/doc4.xml","form_type":"4"}},{"id":2653846,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}}],"security":"Director Stock Option","published_at":"2021-06-28T18:18:35.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":31238,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued. The stock option vests as of 1/36 of the total shares monthly beginning on July 24, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":31238,"derivative":{"exercise_price":16,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":31238},"source":{"system":"sec-edgar","filing":"0001209191-21-043527","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919121043527/doc4.xml","form_type":"4"}},{"id":2655046,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-25T17:01:06.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":47132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in 36 substantially equal monthly installments, with the first installment vesting on June 28, 2021."}],"balance_after":47132,"derivative":{"exercise_price":19,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":47132},"source":{"system":"sec-edgar","filing":"0000899243-21-025981","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000089924321025981/doc4.xml","form_type":"4"}},{"id":2681300,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-04T20:12:45.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":3356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date."}],"balance_after":3356,"derivative":{"underlying":"Common Stock","underlying_shares":3356},"source":{"system":"sec-edgar","filing":"0001209191-21-038459","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919121038459/doc4.xml","form_type":"4"}},{"id":2681299,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T20:12:45.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":12250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date."}],"balance_after":12250,"derivative":{"exercise_price":21.9,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":12250},"source":{"system":"sec-edgar","filing":"0001209191-21-038459","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919121038459/doc4.xml","form_type":"4"}},{"id":3118994,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-08T17:27:47.000Z","date":"2020-06-06","kind":"exercise","acquired":false,"shares":7333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"shares","element":"transactionShares","label":"F4","text":"This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 6, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 6, 2020."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7333},"source":{"system":"sec-edgar","filing":"0001209191-20-035029","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919120035029/doc4.xml","form_type":"4"}},{"id":3118993,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option Grant (right to buy)","published_at":"2020-06-08T17:27:47.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject this option will vest in twelve equal monthly installments commencing July 4, 2020, subject to Reporting Person's continuous service through each such date."}],"balance_after":16500,"derivative":{"exercise_price":1.41,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001209191-20-035029","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919120035029/doc4.xml","form_type":"4"}},{"id":3118992,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-08T17:27:47.000Z","date":"2020-06-06","kind":"exercise","acquired":true,"shares":7333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":16209,"source":{"system":"sec-edgar","filing":"0001209191-20-035029","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919120035029/doc4.xml","form_type":"4"}},{"id":3228019,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2020-03-04T16:28:43.000Z","date":"2020-03-02","kind":"exercise","acquired":false,"shares":8876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest immediately."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest immediately."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8876},"source":{"system":"sec-edgar","filing":"0001209191-20-016090","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919120016090/doc4.xml","form_type":"4"}},{"id":3228018,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2020-03-04T16:28:43.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":8876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest immediately."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest immediately."}],"balance_after":8876,"derivative":{"underlying":"Common Stock","underlying_shares":8876},"source":{"system":"sec-edgar","filing":"0001209191-20-016090","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919120016090/doc4.xml","form_type":"4"}},{"id":3228017,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-04T16:28:43.000Z","date":"2020-03-02","kind":"exercise","acquired":true,"shares":8876,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":8876,"source":{"system":"sec-edgar","filing":"0001209191-20-016090","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919120016090/doc4.xml","form_type":"4"}},{"id":3349952,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":2,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":3,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value of $0.0001","published_at":"2019-12-06T10:23:17.000Z","date":"2019-12-02","kind":"grant","acquired":true,"shares":689655,"price":1.45,"value":999999.75,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are directly held by Aisling Capital IV, LP (\"Aisling\"), and may be deemed to be beneficially owned by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms."}],"balance_after":2718226,"source":{"system":"sec-edgar","filing":"0000899243-19-028646","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000089924319028646/doc4.xml","form_type":"4"}},{"id":3462033,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":4,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":5,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-15T16:15:23.000Z","date":"2019-07-15","kind":"purchase","acquired":true,"shares":2500000,"price":0.6,"value":1500000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Aisling Capital IV, LP (\"Aisling\"). Aisling Capital Partners IV, LP (\"Aisling GP\"), is the general partner of Aisling. Aisling Capital Partners IV LLC (\"Aisling Partners\"), is the general partner of Aisling GP. The individual managing members (\"the Aisling Managers\"), of Aisling Partners are Andrew Schiff, M.D. and Steve Elms. By virtue of these relationships, Aisling GP, Aisling Partners and the Aisling Managers may be deemed to have voting and investment power over the shares held by Aisling. Each of the reporting persons, other than Aisling, disclaims beneficial ownership of the shares held by Aisling, except to the extent of any pecuniary interest therein, if any."}],"balance_after":10100000,"source":{"system":"sec-edgar","filing":"0000899243-19-019602","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000089924319019602/doc4.xml","form_type":"4"}},{"id":3495866,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-10T16:49:11.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":7333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date."}],"balance_after":7333,"derivative":{"underlying":"Common Stock","underlying_shares":7333},"source":{"system":"sec-edgar","filing":"0001209191-19-035829","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919119035829/doc4.xml","form_type":"4"}},{"id":3556782,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":2,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":3,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value of $0.0001","published_at":"2019-04-12T16:15:56.000Z","date":"2019-04-11","kind":"grant","acquired":true,"shares":428571,"price":3.5,"value":1499998.5,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are directly held by Aisling Capital IV, LP (\"Aisling\"), and may be deemed to be beneficially owned by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms."}],"balance_after":2028571,"source":{"system":"sec-edgar","filing":"0000899243-19-010594","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000089924319010594/doc4.xml","form_type":"4"}},{"id":3868776,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":165043,"kind":"organization","name":"AISLING CAPITAL III LP","position":1,"cik":"0001444717","reported_name":"AISLING CAPITAL III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165044,"kind":"organization","name":"Aisling Capital Partners III LP","position":2,"cik":"0001532634","reported_name":"Aisling Capital Partners III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165045,"kind":"organization","name":"Aisling Capital Partners III LLC","position":3,"cik":"0001532635","reported_name":"Aisling Capital Partners III LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165046,"kind":"person","name":"Purcell Dennis J","position":6,"cik":"0001297291","reported_name":"Purcell Dennis J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-12T16:45:29.000Z","date":"2018-07-10","kind":"sale","acquired":false,"shares":1400000,"price":179.43,"value":251202000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are directly held by Aisling Capital III, LP (\"Aisling\"), and indirectly held by Aisling Capital Partners III, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners III LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the \"Investment Committee\") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling."}],"balance_after":2038920,"source":{"system":"sec-edgar","filing":"0000899243-18-019810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000089924318019810/doc4.xml","form_type":"4"}},{"id":3900195,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-08T16:03:24.000Z","date":"2018-06-07","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This grant was made pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest in twelve equal monthly installments through June 7, 2019, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":8000,"derivative":{"exercise_price":18.35,"expiration_date":"2028-06-06","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-18-036653","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919118036653/doc4.xml","form_type":"4"}},{"id":4125123,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":165043,"kind":"organization","name":"AISLING CAPITAL III LP","position":1,"cik":"0001444717","reported_name":"AISLING CAPITAL III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165044,"kind":"organization","name":"Aisling Capital Partners III LP","position":2,"cik":"0001532634","reported_name":"Aisling Capital Partners III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165045,"kind":"organization","name":"Aisling Capital Partners III LLC","position":3,"cik":"0001532635","reported_name":"Aisling Capital Partners III LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165046,"kind":"person","name":"Purcell Dennis J","position":6,"cik":"0001297291","reported_name":"Purcell Dennis J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-20T16:31:26.000Z","date":"2017-12-19","kind":"sale","acquired":false,"shares":250000,"price":80.5,"value":20125000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are directly held by Aisling Capital III, LP (\"Aisling\"), and indirectly held by Aisling Capital Partners III, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners III LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the \"Investment Committee\") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling."}],"balance_after":3438920,"source":{"system":"sec-edgar","filing":"0000950142-17-002235","document":"es1701246_4-loxo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000095014217002235/es1701246_4-loxo.xml","form_type":"4"}},{"id":4150996,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":165043,"kind":"organization","name":"AISLING CAPITAL III LP","position":1,"cik":"0001444717","reported_name":"AISLING CAPITAL III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165044,"kind":"organization","name":"Aisling Capital Partners III LP","position":2,"cik":"0001532634","reported_name":"Aisling Capital Partners III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165045,"kind":"organization","name":"Aisling Capital Partners III LLC","position":3,"cik":"0001532635","reported_name":"Aisling Capital Partners III LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165046,"kind":"person","name":"Purcell Dennis J","position":6,"cik":"0001297291","reported_name":"Purcell Dennis J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-27T19:29:09.000Z","date":"2017-11-22","kind":"sale","acquired":false,"shares":500000,"price":75,"value":37500000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are directly held by Aisling Capital III, LP (\"Aisling\"), and indirectly held by Aisling Capital Partners III, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners III LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the \"Investment Committee\") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling."}],"balance_after":3688920,"source":{"system":"sec-edgar","filing":"0000950142-17-002107","document":"es1701180_4-loxo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000095014217002107/es1701180_4-loxo.xml","form_type":"4"}},{"id":4232641,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-16T16:45:48.000Z","date":"2017-08-16","kind":"purchase","acquired":true,"shares":108601,"price":23.02,"value":2499995.02,"ownership":{"direct":false,"nature":"By Aisling Capital IV LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reportable securities are owned directly by Aisling Capital IV, LP (\"Aisling\"), and held indirectly by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the \"Managers\") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":634455,"source":{"system":"sec-edgar","filing":"0001209191-17-049230","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919117049230/doc4.xml","form_type":"4"}},{"id":4235436,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-08-14T08:21:02.000Z","date":"2017-08-09","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable in 36 equal monthly installments through August 9, 2020, subject to the reporting person's\ncontinuous service as of such vesting dates."}],"balance_after":16000,"derivative":{"exercise_price":26.97,"expiration_date":"2027-08-08","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-17-048677","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919117048677/doc4.xml","form_type":"4"}},{"id":4340503,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-01T13:34:21.000Z","date":"2017-04-28","kind":"disposition_to_issuer","acquired":false,"shares":1589,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option\nmultiplied by the excess, if any, of the Merger Consideration over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":5.06,"expiration_date":"2022-06-14","underlying":"Common Stock","underlying_shares":1589},"source":{"system":"sec-edgar","filing":"0000950142-17-000905","document":"es1700558_4-zeltiq.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000095014217000905/es1700558_4-zeltiq.xml","form_type":"4"}},{"id":4340502,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-05-01T13:34:21.000Z","date":"2017-04-28","kind":"disposition_to_issuer","acquired":false,"shares":1597742,"ownership":{"direct":false,"nature":"By Aisling Capital III, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly\nowned subsidiary of Allergan plc (\"Allergan\"), Blizzard Merger Sub, Inc. (\"Merger Sub\"), and the Issuer (the \"Merger Agreement\"), as approved\nby the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving\ncorporation (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the terms of the Merger Agreement, these shares were cancelled and converted into the right to receive the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly\nowned subsidiary of Allergan plc (\"Allergan\"), Blizzard Merger Sub, Inc. (\"Merger Sub\"), and the Issuer (the \"Merger Agreement\"), as approved\nby the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving\ncorporation (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, these shares were cancelled and converted into the right to receive the Merger Consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares of Common Stock directly held by Aisling Capital III, LP (\"Aisling\") and indirectly held by Aisling Capital Partners III, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners III, LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the \"Managers\") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Andrew Schiff is a member of the Board of Directors of Zeltiq Aesthetics, Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-17-000905","document":"es1700558_4-zeltiq.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000095014217000905/es1700558_4-zeltiq.xml","form_type":"4"}},{"id":4340501,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-05-01T13:34:21.000Z","date":"2017-04-28","kind":"disposition_to_issuer","acquired":false,"shares":13137,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly\nowned subsidiary of Allergan plc (\"Allergan\"), Blizzard Merger Sub, Inc. (\"Merger Sub\"), and the Issuer (the \"Merger Agreement\"), as approved\nby the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving\ncorporation (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the terms of the Merger Agreement, out of the total of 13,137 shares held by the Reporting Person, (i) 11,587 shares were canceled\nand converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the \"Merger\nConsideration\"), and (ii) 1,550 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted\nstock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as\nadjusted based on an exchange ratio."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly\nowned subsidiary of Allergan plc (\"Allergan\"), Blizzard Merger Sub, Inc. (\"Merger Sub\"), and the Issuer (the \"Merger Agreement\"), as approved\nby the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving\ncorporation (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, out of the total of 13,137 shares held by the Reporting Person, (i) 11,587 shares were canceled\nand converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the \"Merger\nConsideration\"), and (ii) 1,550 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted\nstock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as\nadjusted based on an exchange ratio."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes 87 shares of Common Stock held by a trust for the benefit of Mr. Schiff's children."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-17-000905","document":"es1700558_4-zeltiq.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000095014217000905/es1700558_4-zeltiq.xml","form_type":"4"}},{"id":4492221,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":165043,"kind":"organization","name":"AISLING CAPITAL III LP","position":1,"cik":"0001444717","reported_name":"AISLING CAPITAL III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165044,"kind":"organization","name":"Aisling Capital Partners III LP","position":2,"cik":"0001532634","reported_name":"Aisling Capital Partners III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165045,"kind":"organization","name":"Aisling Capital Partners III LLC","position":3,"cik":"0001532635","reported_name":"Aisling Capital Partners III LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165046,"kind":"person","name":"Purcell Dennis J","position":6,"cik":"0001297291","reported_name":"Purcell Dennis J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-12T17:17:02.000Z","date":"2017-01-10","kind":"purchase","acquired":true,"shares":160000,"price":31,"value":4960000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are directly held by Aisling Capital III, LP (\"Aisling\"), and indirectly held by Aisling Capital Partners III, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners III LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the \"Investment Committee\") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling."}],"balance_after":4188920,"source":{"system":"sec-edgar","filing":"0000950142-17-000108","document":"es1700164_4-loxo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000095014217000108/es1700164_4-loxo.xml","form_type":"4"}}]}